NIH Won't Seize Patents To Cut Price Of Cancer Drug Xtandi
By Ryan Davis ( March 21, 2023, 10:24 PM EDT) -- The National Institutes of Health on Tuesday rejected a petition urging the government to lower the price of the prostate cancer drug Xtandi by using so-called march-in rights to take control of the patents on the treatment marketed by Astellas Pharma Inc. and Pfizer Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.